Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While LL-37 acts as a broad-spectrum antimicrobial and immunomodulatory peptide involved in host defense and wound repair, but can also promote inflammation and cancer cell proliferation in some contexts5215, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.
While LL-37 works as a cationic amphipathic 37-amino-acid cathelicidin peptide generated from hCAP18 that disrupts microbial membranes and modulates innate immunity, including chemotaxis, cytokine induction, and NET formation521586, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.
LL-37
CAMP
Thymosin Beta-4
TMSB4X
The clearest overlap between LL-37 and Thymosin Beta-4 is that both converge around Signaling modulator. Their typical research and application settings separate fairly clearly: LL-37 is more often discussed in the realm of Immunology and inflammation and Gastroenterology, whereas Thymosin Beta-4 is more often associated with the realm of Musculoskeletal health, Cardiovascular health, and Dermatology and aesthetics. Both appear to work through Signaling modulator, but the functional emphasis still separates, with LL-37 leaning toward Anti-pathogenic and Immune regulation and Thymosin Beta-4 leaning toward Angiogenesis modulation and Anti-inflammatory. Both come from biologically derived origins with LL-37 in Preclinical development and Thymosin Beta-4 in Clinical phase 2. Thymosin Beta-4 incorporates acetylation features that are not part of LL-37, while their sequence patterns also diverge, with LL-37 showing cationic amphipathic and alpha-helical domain features and Thymosin Beta-4 showing protein-mimetic sequence features.